EUVIMEDEUVIMED entdecken
Crossref

Novel Phenoxyacetic Acid (4‐Aminophenoacetic Acid) Shikonin Ester Kills KRAS Mutant Colon Cancer Cells via Targeting the Akt Allosteric Site

Yudi Ma, Yuqian Sun, Qingqing Tu, Faxiang Lin, Feng Mei, Qingqing Chen, Ting Fu, Liu Yang, Xiaohui Lai, Minkai Yang, Tongming Yin iD, Guihua Lu und 5 weitere

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Yudi Ma und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Institute of Plant Molecular Biology, School of Life Sciences, Nanjing University, Nanjing, Chi…. Hauptthemen laut MEDLINE: Naphthoquinones, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins p21(ras), Colonic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Program for Changjiang Scholars and Innovative Research Team in University, Natural Science Foundation of Jiangsu Bureau of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K‐Akt axis is abnormally activated in KRAS‐mutated colorectal cancer and is considered to be a potential therapeutic target. A novel series of phenoxyacetic acid (4‐aminophenoacetic acid) shikonin esters was designed by computer‐aided drug design (CADD) and synthesized as Akt allosteric inhibitors. Most compounds exhibited greater anti‐proliferative activity compared to the positive control MK2206, while also demonstrating lower cytotoxicity against normal cells than shikonin. One of the promising candidates, L8, was selected for further biological evaluation. Docking studies indicated that L8 effectively bound to the allosteric site of Akt through hydrophobic and hydrogen interactions. Enzyme activity and kinetics assessments revealed that L8 bound to Akt with a Kd of 2.07 × 10 −6 M and inhibited its activity. Further intracellular assays, including western blotting, enzyme activity assay, flow cytometry, etc., verified that L8 mediated the death of two KRAS‐mutant colon cancer cell lines HCT116 (KRAS G13D ) and HCT‐8 (KRAS G12A ) cells by inactivating Akt, causing tumor cell apoptosis, cell cycle arrest, and interfering with tumor cell invasion and metabolism. A 3D‐QSAR model was constructed to understand the relationship between the structure of the shikonin derivatives and their anti‐proliferative activity. The in silico ADMET and toxicity prediction studies revealed a few undesired pharmacokinetic attributes of our compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaphthoquinonesProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Colonic NeoplasmsAntineoplastic AgentsHumansApoptosisMolecular Docking SimulationAllosteric SiteCell ProliferationCell Line, TumorMutationEstersHCT116 Cells

Stichwörter der Autor:innen

AktKRAS mutantcolorectal cancerdrug designshikonin

Substanzen

NaphthoquinonesProto-Oncogene Proteins c-aktshikoninProto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic AgentsEsters

Autor:innen und Institutionen

  • State Key Laboratory of Pharmaceutical Biotechnology, Institute of Plant Molecular Biology, School of Life Sciences, Nanjing University, Nanjing, China.
  • Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, China.
  • School of Life Sciences, Huaiyin Normal University, Huaian, China.
  • School of Pharmacy, Changzhou University, Changzhou, China.
  • School of Life Sciences and Chemical Engineering, Jiangsu Second Normal University, Nanjing, China.

ORCID-Profile: Tongming Yin, Yonghua Yang

Förderung

  • National Natural Science Foundation of China
  • Program for Changjiang Scholars and Innovative Research Team in University
  • Natural Science Foundation of Jiangsu Bureau of Science and Technology
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Ma, Y., Sun, Y., Tu, Q., Lin, F., Mei, F., Chen, Q., Fu, T., Yang, L., Lai, X., Yang, M., Yin, T., Lu, G., Qi, J., Lin, H., Wen, Z., Yang, Y., & Han, H. (2025). Novel Phenoxyacetic Acid (4‐Aminophenoacetic Acid) Shikonin Ester Kills KRAS Mutant Colon Cancer Cells via Targeting the Akt Allosteric Site. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70125

Vancouver

Ma Y, Sun Y, Tu Q, Lin F, Mei F, Chen Q, et al. Novel Phenoxyacetic Acid (4‐Aminophenoacetic Acid) Shikonin Ester Kills KRAS Mutant Colon Cancer Cells via Targeting the Akt Allosteric Site. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70125

BibTeX
@article{Ma2025,
  author = {Ma, Yudi and Sun, Yuqian and Tu, Qingqing and Lin, Faxiang and Mei, Feng and Chen, Qingqing and Fu, Ting and Yang, Liu and Lai, Xiaohui and Yang, Minkai and Yin, Tongming and Lu, Guihua and Qi, Jinliang and Lin, Hongyan and Wen, Zhongling and Yang, Yonghua and Han, Hongwei},
  title = {Novel Phenoxyacetic Acid (4‐Aminophenoacetic Acid) Shikonin Ester Kills KRAS Mutant Colon Cancer Cells via Targeting the Akt Allosteric Site},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70125}
}
Kostenlos starten →